BioTuesdays

Axsome Therapeutics names David Marek as CCO

Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31.

Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager of the neuroscience business unit. He was previously VP of marketing of Amgen’s U.S. inflammation and nephrology business. Prior to joining Amgen, Mr. Marek was EVP of consumer services and commercial strategy officer at WebMD; and the managing director of Saatchi & Saatchi Healthcare Advertising.

“Mr. Marek’s expertise in both digital and traditional media, creative commercialization strategies, value and access, and new product launches, is an important addition to Axsome as we create and execute our commercial plans and continue our growth into a leading CNS biopharmaceutical company,” Dr. Herriot Tabuteau, Axsome’s CEO, said in a statement.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.